Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Poll|November 14, 2014
Dime-Sized, Red, Scaly Patch: Your Dx?
A 58-year-old man asks about this painless lesion on his left third digit. It does not itch, burn, or sting and there are no other similar lesions. He had a history of basal cell carcinoma on the arm and several more recent actinic keratoses on his scalp. What’s your diagnosis?
Advertisement
A 58-year-old man asks about this painless lesion on his left third digit. It does not itch, burn, or sting and there are no other similar lesions. He had a history of basal cell carcinoma on the arm and several more recent actinic keratoses on his scalp.
What’s your diagnosis?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5